

IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE

|                                |   |                       |
|--------------------------------|---|-----------------------|
| NOVO NORDISK INC. and          | ) |                       |
| NOVO NORDISK A/S,              | ) |                       |
|                                | ) |                       |
| Plaintiffs,                    | ) |                       |
|                                | ) |                       |
| v.                             | ) | C.A. No. 22-294 (CFC) |
|                                | ) |                       |
| RIO BIOPHARMACEUTICALS INC.    | ) |                       |
| and EMS S/A,                   | ) |                       |
|                                | ) |                       |
| Defendants.                    | ) |                       |
| <hr/>                          |   |                       |
| NOVO NORDISK INC. and          | ) |                       |
| NOVO NORDISK A/S,              | ) |                       |
|                                | ) |                       |
| Plaintiffs,                    | ) |                       |
|                                | ) |                       |
| v.                             | ) | C.A. No. 22-296 (CFC) |
|                                | ) |                       |
| SUN PHARMACEUTICAL             | ) |                       |
| INDUSTRIES LTD. and SUN        | ) |                       |
| PHARMACEUTICAL INDUSTRIES,     | ) |                       |
| INC.,                          | ) |                       |
|                                | ) |                       |
| Defendants.                    | ) |                       |
| <hr/>                          |   |                       |
| NOVO NORDISK INC. and          | ) |                       |
| NOVO NORDISK A/S,              | ) |                       |
|                                | ) |                       |
| Plaintiffs,                    | ) |                       |
|                                | ) |                       |
| v.                             | ) | C.A. No. 22-297 (CFC) |
|                                | ) |                       |
| ZYDUS WORLDWIDE DMCC, ZYDUS    | ) |                       |
| PHARMACEUTICALS (USA) INC. and | ) |                       |
| ZYDUS LIFESCIENCES LIMITED,    | ) |                       |
|                                | ) |                       |
| Defendants.                    | ) |                       |

NOVO NORDISK INC. and  
NOVO NORDISK A/S,

Plaintiffs,

v.

DR. REDDY'S LABORATORIES, LTD.  
and DR. REDDY'S LABORATORIES,  
INC.,

Defendants.

NOVO NORDISK INC. and  
NOVO NORDISK A/S,

Plaintiffs,

v.

ALVOGEN, INC.,

Defendant.

C.A. No. 22-298 (CFC)

C.A. No. 22-299 (CFC)

**[PROPOSED] SCHEDULING ORDER**

This 29<sup>th</sup> day of June, 2022, pursuant to the Court's June 6, 2022 Order directing the parties to confer about scheduling and discovery limitations, the parties have discussed pretrial management issues, have determined after discussion that the matter cannot be resolved at this juncture by settlement, voluntary mediation, or binding arbitration, and have prepared this proposed scheduling order;

IT IS ORDERED that:

1. Case Consolidation and Caption Modification. These actions are consolidated for all purposes, and all papers shall be filed in C.A. No. 22-cv-294-CFC. The Caption shall be modified to include the words “ANDA CASE” immediately below the Civil Action Number.

2. Relevant Deadlines and Dates. All relevant deadlines and dates established by this Order are set forth in the chart attached as Exhibit A. The expiration date of any applicable 42-month period imposed pursuant to 21 U.S.C. §§ 255(j)(5)(B)(iii), 255(j)(5)(F)(ii) is set forth in the first row of the chart.

3. Initial Disclosures. Unless otherwise agreed to by the parties, the parties shall make their initial disclosures required by Federal Rule of Civil Procedure 26(a)(1) and their initial disclosures required by Paragraph 3 of the District of Delaware Default Standard on or before **14 days after entry of the Scheduling Order.**

4. Production of the ANDAs. As required by the Standing Order Regarding Hatch-Waxman Cases in Which Infringement is Alleged, each of the five Defendant Groups listed below confirm that they produced to Novo Nordisk Inc. and Novo Nordisk A/S (collectively, “Plaintiffs”), on the date

indicated below, the entire Abbreviated New Drug Application (“ANDA”) that is the basis of the Defendant Group’s alleged infringement:

- (a) Alvogen Inc. (“Alvogen”) confirms that it produced a copy of the entire ANDA No. 215920 on May 16, 2022;
- (b) Dr. Reddy’s Laboratories, Ltd. and Dr. Reddy’s Laboratories, Inc. (collectively, “DRL”) confirm that they produced a copy of the entire ANDA No. 216417 on May 4, 2022;
- (c) Rio Biopharmaceuticals Inc. and EMS S/A (collectively, “Rio”) confirm that they produced a copy of the entire ANDA No. 216305 on May 9, 2022;
- (d) Sun Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries, Inc. (collectively, “Sun”) confirm that they produced a copy of the entire ANDA No. 216478 on June 7, 2022; and
- (e) Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc., and Zydus Lifesciences Limited (collectively, “Zydus”) confirm that they produced a copy of the entire ANDA No. 215704 on May 9, 2022.

**Plaintiffs’ Position:** A number of asserted patents relate to the device used to administer Ozempic<sup>®</sup>. Plaintiffs therefore requested early production of



Computer-Aided Design (CAD) files, the Design History File, and samples of the device described in each Defendant Group's ANDA to facilitate Plaintiffs' infringement assessment and selection of claims to assert. The parties were unable to reach agreement on early production of the requested materials. Production of these materials is necessary to Plaintiffs' identification of claims asserted in the Preliminary Disclosure of Asserted Claims and preparation of Infringement Contentions. Defendants' failure to timely produce these materials in response to any Requests for Production served by Plaintiffs will constitute good cause for amending Plaintiffs' Disclosure of Asserted Claims and Infringement Contentions. The materials Plaintiffs will rely on to show infringement in this Hatch-Waxman litigation are not publicly available and are uniquely in Defendants' possession. Moreover, the materials relied on by Plaintiffs to show infringement may very well be different from the materials produced by Defendants' in support of Defendants' non-infringement positions. Accordingly, Plaintiffs' dispute any suggestion that their need for discovery of Defendants' devices would somehow be satisfied by Defendants' production obligations under Paragraph 6.



# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.